OnKöl integrates Gemalto technology
AMSTERDAM – OnKöl has integrated a wireless module from digital security company Gemalto into its smart hub. “Gemalto’s reputation, wide variety of high quality, industrial-grade modules and breadth of mHealth experience convinced us that their technology was the best fit for our product,” said Erich Jacobs, CEO of OnKöl, in a statement. “It allowed us to deliver a hub that is effortless to set up, use, and scale to support OnKöl business growth in the future.” The OnKöl hub can notify family members, caregivers and medical professionals of everything from vital signs to medication reminders to emergency response situations, straight out of the box. Gemalto’s M2M module securely manages OnKöl’s remote patient monitoring services in the cloud to simplify deployment, personalization and software updates. The patient can easily connect health and home monitoring devices like blood pressure cuffs and heart monitors, and Gemalto’s module encrypts and sends the gathered information to the OnKöl platform, where it is delivered to caregivers and can even be logged into a patient’s electronic medical records.
Welltok names Power CFO
DENVER – Welltok, a consumer health enterprise Software as a Service company, has appointed Chris Power as CFO. “Chris is an exceptional leader who brings tremendous financial depth and operating know-how to our fast-growing organization,” said Jeff Margolis, chairman and CEO of Welltok, in a statement. Power most recently served as CFO of Paycor. In his new position, he will be responsible for guiding Welltok’s continued growth, and driving margin expansion and profitability. “I’m passionate about the power of big data and SaaS to transform the healthcare industry,” said Power in a statement. “I look forward to not only helping the organization prepare for the future but also serving our customers as they strive to help health care consumers achieve and sustain their optimal health.”
CareCentrix, Medullan team to develop virtual care tools
HARTFORD, Conn. – CareCentrix is partnering with digital health company Medullan to develop virtual care tools that connect providers, patients and payers. “The home is underappreciated as an alternative to other care settings, even though patients want to be there,” explained John Driscoll, CEO of CareCentrix, a home health management solutions provider, in a statement. “Technological advances, however, do not matter if you cannot successfully engage and connect the healthcare team.” Medullan’s digital expertise and care experience platform, VARA, will combine with CareCentrix’s HomeBridge technology for a personalized digital experience to optimize patient care. “We look forward to co-creating the new standard for virtual health care experiences in post-acute care with CareCentrix,” said Ahmed Albaiti, CEO of Medullan, in a statement.
Preventice receives Strategy Leadership Award
MINNEAPOLIS – Preventice Solutions received the 2017 Frost & Sullivan Product Line Strategy Leadership Award for its remote cardiac monitoring portfolio of technologies and services. The company’s portfolio includes wearable monitors and diagnostic monitoring services. “Preventice is an emerging industry leader for cardiac remote patient monitoring that provides a comprehensive solution for physicians and patients alike,” said Patrick Riley, principal analyst at Frost & Sullivan, a growth strategy company, in a statement. Preventice’s customizable and configurable platform enables arrhythmia monitoring, as well as remote monitoring using different types of devices. “Our focus from the beginning has been on understanding and addressing physician and patient needs with a comprehensive portfolio of monitoring technologies and services,” said Jon Otterstatter, CEO of Preventice, in a statement. “For physicians, it means access to data on how their patients are doing, and for patients, it’s technology that allows them to go about their daily activities without restrictions.”
McAndrews named to Teladoc board
PURCHASE, N.Y. – Telehealth provider Teladoc has appointed Brian McAndrews to its board of directors. “As we expand our use of data and analytics along with AI to help generate the best outcomes, Brian’s knowledge in this area will not only help us achieve technological milestones, but also communicate that value to our members across the globe,” said Jason Gorevic, president and CEO of Teladoc, in a statement.
McAndrews is the former CEO, president and chairman of Pandora Media, and currently sits on the board of Amplero. “There is a tremendous opportunity to leverage AI and analytics for enhanced communication with and to bring to bear better healthcare outcomes for current and prospective Teladoc members alike,” said McAndrews in a statement.
DarioHealth joins HighTechXL accelerator
CAESAREA, Israel and EINDHOVEN, Netherlands – Digital diabetes company DarioHealth Corp. has joined the HighTechXL accelerator with a goal of bringing personalized health care management to diabetes and pre-diabetes patients around the world. “We believe the industry is transforming from a device-driven industry to a personalized managed care, data and clinical outcome driven industry,” said Erez Raphael, chairman and CEO of DarioHealth, in a statement. “We are looking forward to collaborate with the accelerator team and find new ways to accelerate our growth.” Backed by an alliance of corporations and regional organizations, the HighTechXL Acceleration program is a three-month program designed to accelerate startups to their next stage of development, including to help them gain broader customer traction and secure development partnerships. DarioHealth develops cloud-based diabetes platforms that include a native mobile solution helping patients to manage diabetes-related information and a platform that facilitates coaching. The all-in-one Dario Blood Glucose Monitoring System is capable of sharing real-time results with healthcare professionals via the personalized AI-driven application.
98point6 raises $19.5M for telemedicine app
SEATTLE –Health care technology company 98point6 has raised $19.5 million in Series B funding to accelerate product development and to expand its telemedicine service across the U.S. “98point6 is creating a new approach to primary care where everyone wins: consumers, physicians, businesses, payers and provider groups,” said Robbie Cape, co-founder and CEO of 98point6, in a statement. The company developed an app that allows users to communicate with board-certified physicians at no charge. The app is currently not available everywhere; a pilot program will launch in early 2018.
Cardio acquired by Halma
SAO PAOLO, Brazil –Cardiac monitoring company Cardios has been acquired by Halma, a U.K.-based safety, health and environmental technology group, and is now part of Halma’s Medical Sector. All Cardios leadership and operations will remain based in Brazil, and the company will now have access to Halma’s resources to continue its growth, said Lisa Wallner, Halma public relations, in a statement.
TelaCare adds access to specialty providers
FISHERS, Ind. – Telemedicine provider TelaCare has incorporated unlimited access to specialty providers into its services. “Patients seeking virtual care will have even greater access and more care options thanks to this unique specialty offering from TelaCare,” said Larry Jones, CEO of TelaCare, in a statement. “Adding these additional telemedicine services to our patients at no additional charge helps us to build upon our goal of offering a broad suite of solutions to our employer and health plan partners, all with a common goal of providing consumers with better access to high quality care at a lower cost.”
BioSensics receives $2.5M NIH grant for Huntington’s wearable
WATERTOWN, Mass. – Wearable sensor developer BioSensics has received $2.5 million in grant funding from the National Institutes of Health to develop a wearable monitor for patients with Huntington’s disease.
“HD patients often have to travel long distances to be seen by knowledgeable HD clinicians,” said Dr. George Yohrling, senior director of mission and scientific affairs of the Huntington’s Disease Society of America, in a statement. “The development and eventual integration of wearable biosensors into a HD clinic would allow for remote monitoring of a patient’s motor symptoms and could alleviate this unnecessary burden on the entire HD family.”
The device, called HDWear, is powered by BioSensics’ PAMSys sensor technology and enables continuous remote monitoring of Huntington’s disease motor symptoms.
The two-year project will build on pilot work performed in collaboration with the University of Rochester Medical Center and Teva Pharmaceuticals, and published in the Journal of Huntington’s Disease in 2016. The study demonstrated a wearable sensor solution for remotely monitoring the severity of upper extremity chorea in Huntington’s disease.
HDWear will provide real-time, remote access to quantitative motor symptom scores like the Unified Huntington’s Disease Rating Scale, previously only possible through in-clinic assessments.
As a part of the project, BioSensics and the University of Rochester Medical Center will conduct a clinical study to evaluate HDWear for detecting pharmacological response to anti-chorea medication or subtle motor abnormalities in the premanifest stage of Huntington’s disease.
“We are excited to be working with BioSensics on evaluating wearable sensors to obtain objective, high frequency, and potentially sensitive assessments of individuals with Huntington’s disease, both inside and outside the clinic,” said Dr. Ray Dorsey, director of the Center for Health & Technology at University of Rochester Medical Center, in a statement.
“We look forward to creating a comprehensive telecare solution for Huntington’s disease to facilitate clinical research and new drug development, and ultimately to improve and revolutionize HD care and care coordination,” said Dr. Joseph Gwin, vice president of research and development at BioSensics.
Use of digital diabetes management tools helps control glucose, study finds
WALTHAM, Mass. – Digital therapy for diabetes management helps patients achieve glucose control more rapidly than traditional methods, according to a study presented recently at the annual meeting of the European Association for the Study of Diabetes.
The study looked at patients whose insulin therapy is guided by Glytec’s Glucommander software and found that they not only achieved glucose control rapidly, but also, with ongoing personalized dose adjustments, successfully maintained A1C reductions long term.
“For the increasing number of patients whose baseline A1C is at or above 9%, getting to target is one thing, but staying there is another,” said Dr. Andrew Rhinehart, chief medical officer at Glytec.
The study sought to examine the frequency of insulin dose adjustments needed over time to ensure that patients maintain A1C reductions and do not experience loss or deterioration of glucose control. A literature review identified no specific evidence designating how often providers should review blood glucose measurements and titrate insulin after a patient reaches their target A1C; one of the study aims was to fill this research void.
Once patients are titrated to goal with Glucommander, researchers found, the cloud-hosted software remains active, synthesizing daily blood glucose measurements, performing personalized analyses to determine whether and when insulin dose adjustments are needed, and monitoring data to identify patients experiencing out-of-range highs or lows or not testing often enough.
The study analyzed outcomes of 74 patients. The median time between insulin dose adjustments—after the initial three-month treatment period—was 57 days.
“This means that once Glucommander titrated these patients to goal, continued analyses of patterns in their blood glucose indicated that additional insulin dose adjustments were needed, on average, every eight weeks,” said Rhinehart. “This confirms that the usual and customary practice of patients waiting three to six months for a follow-up visit is not sufficient to maintain glucose control and may increase risks of hyperglycemia and hypoglycemia.”
Among the patients included in the study, severe hypoglycemia measured as a percent of blood glucose values was only 0.05%. The study also found reductions in A1C from a baseline average of 10.3% to 8.0% at three months, 8.0% at six months and 7.8% at 12 months; also, a median time of seven days for patients to reach their prescribed glucose goal.
“We’ve been very purposeful in our design of Glucommander to ensure maximum efficiency, scalability and ease of use for clinicians,” said Robby Booth, senior vice president of research and development at Glytec, in a statement. “They don’t have to wade through troves of data to perform manual calculations and they don’t have to question whether or when it’s appropriate to make dose adjustments. And because this happens remotely, an intervention takes only a couple of minutes, which translates to less time and overhead in treating patients with diabetes, better margins and greater profitability.”